Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With <scp>B‐Cell</scp> Lymphomas-Reference-Cited by-同舟云学术

Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas

Published:2022-09-27 Issue:5 Volume:112 Page:1108-1119
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Li Tommy¹^ORCID,Hiemstra Ida H.²,Chiu Christopher¹^ORCID,Oliveri Roberto S.³,Elliott Brian¹,DeMarco Dena¹,Salcedo Theodora¹,Egerod Frederikke Lihme³,Sasser Kate¹,Ahmadi Tahamtan¹,Gupta Manish¹

Affiliation:

1. Genmab Princeton New Jersey USA

2. Genmab Utrecht The Netherlands

3. Genmab A/S Copenhagen Denmark

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2729

Reference16 articles.

1. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

2. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing

3. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

4. Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents

5. Novel Semi-Mechanistic Model Leveraging Preclinical and Clinical Data to Inform the Recommended Phase 2 Dose (RP2D) Selection for Epcoritamab (DuoBody CD3xCD20)

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Joint use of population pharmacokinetics and machine learning for prediction of valproic acid plasma concentration in elderly epileptic patients;European Journal of Pharmaceutical Sciences;2024-10

2. Prediction of teicoplanin plasma concentration in critically ill patients: a combination of machine learning and population pharmacokinetics;Journal of Antimicrobial Chemotherapy;2024-08-29

3. Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T‐Cell Engagers Development in Oncology;Clinical Pharmacology & Therapeutics;2024-07-04

4. Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T‐Cell Engager, Using Population Pharmacokinetics and Exposure–Response Analysis;Clinical Pharmacology & Therapeutics;2024-06-28

5. Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology;Clinical Pharmacology & Therapeutics;2024-06-02